Investing.com | Author Sam Boughedda
Published Jan 26, 2023 06:14
By Sam Boughedda
GoodRx Holdings Inc (NASDAQ:GDRX) shares are down for a second day in a row after Amazon (NASDAQ:AMZN) announced Tuesday that it is rolling out a new product, RxPass, which provides the company's U.S. Prime members with access to generic medications that treat more than 80 common health conditions for just $5 a month.
GoodRx is currently down more than 9%.
Reacting to the news, Citi analysts, who have a Buy rating and $7 per share price target on GDRX, told investors that while it is still more economical to use GoodRx for consumers taking one drug, for the 30% of Americans using two or more drugs, RxPass will be a "very compelling offering," particularly for consumers who are already Prime members.
"We also think this will pressure GoodRx Gold membership (which was just raised to $9.99/month), although GoodRx Gold provides additional benefits such as telehealth visits for $19 (vs $35 via Amazon Clinic). We think GoodRx will need to accelerate the pace of product innovation (see for example GDRX's new commercial offering with ESI to fend off the AMZN threat. We size the max threat at $75-80M of potential lost revenue," writes the analysts.
Wells Fargo analysts reacted to the news with less worry, stating the RxPass announcement "appears to be more bark than bite."
"While Amazon's competitive ambitions shouldn't be dismissed, the move in GDRX appears overdone, as we estimate RxPass addresses ~0.5% of annual domestic generic Rx volumes," argued the analysts, who have an Equal Weight rating and $5.50 price target on GoodRx shares.
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.